Corbus Pharmaceuticals Hldgs Inc (CRBP) Stock Price, Quote & News

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 963 0100

Fax: 617 663 6085

Website: www.corbuspharma.com

Address:

500 River Ridge Drive, Norwood, United States

Hepacke Oct. 6 at 8:42 PM

$CRBP Q4 2025: Completion of CRB-701 dose optimization, determination of the RP2D, and first data from CRB-601.October 2025 (Oct 19): Major presentation/poster + KOL event at ESMO for CRB-701 data.

0 · Reply

Hepacke Oct. 6 at 4:31 PM

$CRBP Der nächste offizielle Termin für Corbus Pharmaceuticals Holdings, Inc. (CRBP) ist: 19. Oktober 2025, 10:00 Uhr CEST — Präsentation auf dem ESMO 2025 Congress, Poster # 967P Außerdem ist ein Q3-2025 Earnings Release derzeit für 10. November 2025 geplant

0 · Reply

Mavrick3 Oct. 5 at 11:19 PM

$CRBP Does anyone know the date the next phase announcement date is this month??

1 · Reply

Hepacke Oct. 3 at 7:44 PM

$CRBP jetzt geht es an die erste Mauer bei 15$ , lass uns die Mauer einreißen ... BULLISCH

0 · Reply

rangerhawkeye Oct. 3 at 6:52 PM

$CRBP nice move this month, still long

0 · Reply

Cricket23 Oct. 3 at 4:43 PM

$CRBP I am loving this upward trend we are seeing from CRBP. smart investors are starting t pick up on their valuable pipeline of products. With all the positive news coming out soon about updates to their studies, we could easily see $20-30 very soon. Holding Strong!

0 · Reply

silentmaxx Oct. 3 at 1:54 PM

$CRBP

1 · Reply

silentmaxx Oct. 2 at 2:18 PM

$CRBP

0 · Reply

Mavrick3 Oct. 2 at 3:14 AM

$CRBP

0 · Reply

kshonstocks Oct. 2 at 1:15 AM

$CRBP on higher volume

0 · Reply

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Jun 25, 2025, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 24, 2025, 4:05 PM EDT - 3 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 17, 2025, 3:42 PM EDT - 3 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

May 22, 2025, 8:00 AM EDT - 4 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Mar 28, 2025, 8:00 AM EDT - 6 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Feb 14, 2025, 7:30 AM EST - 8 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 11, 2025, 7:30 AM EST - 8 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Jan 28, 2025, 8:00 AM EST - 8 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 6, 2025, 8:00 AM EST - 9 months ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 10 months ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

Dec 3, 2024, 7:00 AM EST - 10 months ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 11, 2024, 4:12 AM EST - 11 months ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2024, 9:19 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Jan 30, 2024, 6:55 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Jan 30, 2024, 7:13 AM EST - 1 year ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 29, 2024, 2:17 PM EST - 1 year ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 7:18 AM EST - 1 year ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 26, 2024, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 23, 2024, 8:00 AM EST - 1 year ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 9, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Dec 18, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Nov 7, 2023, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

Hepacke Oct. 6 at 8:42 PM

$CRBP Q4 2025: Completion of CRB-701 dose optimization, determination of the RP2D, and first data from CRB-601.October 2025 (Oct 19): Major presentation/poster + KOL event at ESMO for CRB-701 data.

0 · Reply

Hepacke Oct. 6 at 4:31 PM

0 · Reply

Mavrick3 Oct. 5 at 11:19 PM

$CRBP Does anyone know the date the next phase announcement date is this month??

1 · Reply

Hepacke Oct. 3 at 7:44 PM

$CRBP jetzt geht es an die erste Mauer bei 15$ , lass uns die Mauer einreißen ... BULLISCH

0 · Reply

rangerhawkeye Oct. 3 at 6:52 PM

$CRBP nice move this month, still long

0 · Reply

Cricket23 Oct. 3 at 4:43 PM

0 · Reply

silentmaxx Oct. 3 at 1:54 PM

$CRBP

1 · Reply

silentmaxx Oct. 2 at 2:18 PM

$CRBP

0 · Reply

Mavrick3 Oct. 2 at 3:14 AM

$CRBP

0 · Reply

kshonstocks Oct. 2 at 1:15 AM

$CRBP on higher volume

0 · Reply

shlomiko Sep. 30 at 6:59 PM

$CRBP

0 · Reply

birdmine Sep. 26 at 6:36 PM

$CRBP it looks like they lifted the restrictions on this stock.

0 · Reply

Cricket23 Sep. 25 at 7:37 PM

$CRBP Got a lot of positive news upcoming very soon. Going to look forward to hearing positive updates from the company. Stock price will push much higher than its current prices. This company has a lot of value in their pipeline of products. $20-30 range we will see very soon.

1 · Reply

shlomiko Sep. 22 at 1:35 PM

$CRBP

0 · Reply

PaulinaCrist1051 Sep. 21 at 6:19 AM

$CRBP Biotech with clinical data upcoming. High volatility expected. Binary event risk.

0 · Reply

RadioIsotope25 Sep. 19 at 3:54 PM

Webinar Registration - Radiopharm Theranostics Nasdaq: RADX $LNTH $SABS $CRBP $PYXS https://us02web.zoom.us/webinar/register/WN_Kk2s77p3SbK2XaKHym-SXA#/registration

0 · Reply

GMExAPE Sep. 17 at 9:28 PM

RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $LOCL $LAZR $CRBP $PRE $KYTZ ww now

0 · Reply

EfamhS Sep. 17 at 6:07 PM

$CRBP 🎉 https://finance.yahoo.com/news/fda-grants-fast-track-designation-120000929.html

0 · Reply

shoagh12 Sep. 17 at 3:51 PM

$CRBP 100 soon

1 · Reply

JarvisFlow Sep. 17 at 10:30 AM

HC Wainwright & Co. has updated their rating for Corbus Pharmaceuticals ( $CRBP ) to Buy with a price target of 40.

0 · Reply

justme_DC Sep. 16 at 8:06 PM

$CRBP NOT a "squeeze player" AKA lottery ticket player. But with this current sick SI and shorts that have not returned today....NOW is the time to follow it up with a substantive PR. Fast track was great, but typical action is that it retraces within1-3 days. They need something meaninful. Otherwise, just think it will continue to trickle down. GL to us all

0 · Reply

BioTuesdays Sep. 16 at 7:11 PM

$CRBP has announced that the FDA has granted fast track designation to its next-generation Nectin-4 antibody drug conjugate CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy https://biotuesdays.com/2025/09/16/fda-grants-corbus-fast-track-designation-for-crb-701-in-hnscc/

0 · Reply

Market Cap	181.74M
Revenue (ttm)	0.00
Net Income (ttm)	-40.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	165,900
Avg Vol	130,636
Day's Range	N/A - N/A
Shares Out	12.26M
Stochastic %K	85%
Beta	2.84
Analysts	Strong Sell
Price Target	$40.67